Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Rudolph E. Tanzi
Massachusetts General Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Amylyx Pharmaceutical Corporation
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Tanzi has a financial interest in Amylyx Pharmaceutical Corporation, a company primarily focused on developing Alzheimer’s disease therapeutics. The research project, which seeks to identify novel-drug sensitive resilience associated pathways in AD and drugs that enhance RA pathways, will establish the basis for a therapeutic intervention that can prevent or reduce cognitive decline related to AD. The results of the study could therefore be of interest to the company. The Partners Committee on Outside Activities review panel evaluated the financial interest in connection with this research project and determined that, based on the close connection between the company’s interests and the research, the financial interest could directly and significantly affect the design, conduct, or reporting of the research.
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.
Project Narrative: There are individuals who remain cognitively intact despite the presence of neuropathological features associated with a fully symptomatic stage of Alzheimer's disease. The study discovers the pathways these resilient AD controllers have in common, and uses them to develop drugs that mimic their activity in a brain-in-a-dish model, and confirms that they protect mice against Alzheimer's. If we are successful, experiments on safe to use drugs could be performed to protect humans against Alzheimer's.
Filed on July 16, 2019.
Tell us what you know about Rudolph E. Tanzi's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Rudolph E. Tanzi filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Rudolph E. Tanzi | Massachusetts General Hospital | Conflict of Interest | AZTherapies, Inc. | $20,000 - $39,999 |
| Rudolph E. Tanzi | Massachusetts General Hospital | Conflict of Interest | Jefferson Pharmaceuticals | $20,000 - $39,999 |
| Rudolph E. Tanzi | Massachusetts General Hospital | Conflict of Interest | AZTherapies, Inc. | Value cannot be readily determined |
| Rudolph E. Tanzi | Massachusetts General Hospital | Conflict of Interest | Jefferson Pharmaceuticals | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.